420 related articles for article (PubMed ID: 26437312)
1. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
[TBL] [Abstract][Full Text] [Related]
2. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
Kaur AD; McQueen A; Jan S
J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
[TBL] [Abstract][Full Text] [Related]
3. Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis.
Martínez-Raga J; González Saiz F; Pascual C; Casado MA; Sabater Torres FJ
Eur Addict Res; 2010; 16(1):31-42. PubMed ID: 19923837
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
7. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
[TBL] [Abstract][Full Text] [Related]
8. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
11. Comparison of costs and utilization among buprenorphine and methadone patients.
Barnett PG
Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
[TBL] [Abstract][Full Text] [Related]
12. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine for opiate addiction: potential economic impact.
Rosenheck R; Kosten T
Drug Alcohol Depend; 2001 Aug; 63(3):253-62. PubMed ID: 11418229
[TBL] [Abstract][Full Text] [Related]
14. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
Winstock AR; Lea T; Ritter A
Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
[TBL] [Abstract][Full Text] [Related]
15. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
[TBL] [Abstract][Full Text] [Related]
19. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
20. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
